Litcius/Paper detail

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

Kristin B. Highland, Oliver Distler, Masataka Kuwana, Yannick Allanore, Shervin Assassi, Arata Azuma, Arnaud Bourdin, Christopher P Denton, Jörg H W Distler, Anna‐Maria Hoffmann‐Vold, Dinesh Khanna, Maureen D. Mayes, Ganesh Raghu, Madelon C Vonk, Martina Gahlemann, Emmanuelle Clerisme-Beaty, M Girard, Susanne Stowasser, Donald F. Zoz, Toby M. Maher

2021The Lancet Respiratory Medicine212 citationsDOIOpen Access PDF

Topics & Concepts

NintedanibMedicineSubgroup analysisInterstitial lung diseaseMycophenolateInternal medicineLungIdiopathic pulmonary fibrosisMeta-analysisTransplantationSystemic Sclerosis and Related DiseasesInflammatory Myopathies and DermatomyositisMultiple Sclerosis Research Studies
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial | Litcius